Sotatercept on Central Cardiopulmonary Performance and Peripheral Oxygen Transport During Exercise in Pulmonary Arterial Hypertension

Overview

About this study

The purpose of this study is to test the hypothesis that sotatercept therapy improves exertional right heart reserve as assessed by exercise pulmonary artery pressure adjusted for cardiac output during peak exercise (primary endpoint).

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria

Subjects are eligible to be randomized in the study only if all the following inclusion criteria and none of the exclusion criteria apply.

  • Informed consent obtained before any trial-related activities. Trial-related activities are any procedures that are carried out as part of the trial, including activities to determine suitability for the trial.
  • Age ≥ 18 years at the time of signing informed consent.
  • NYHA Class II-IV.
  • LVEF ≥ 40 % within the preceding year.
  • No recent initiation of pulmonary vasodilator in the last 60 days.
  • Pulmonary arterial hypertension by right heart catheterization (Mean PA pressure ≥ 20 mmHg with PVR>2 Wood units) with no evidence of heart failure with preserved ejection fraction (exercise PCWP <25 mm Hg).
  • Symptomatic PAH patients with plan to undergo exercise RHC for reassessment of exertional symptoms.

Exclusion Criteria

Subjects are excluded from the trial if any of the following criteria apply:

  • Myocardial infarction, stroke, hospitalization for heart failure, unstable angina pectoris or transient ischemic attack within 30 days prior to the day of screening.
  • Planned coronary, carotid, or peripheral artery revascularization.
  • Any other condition judged by the investigator to be the primary cause of dyspnea (such as heart failure due to restrictive cardiomyopathy or infiltrative conditions (e.g., amyloidosis), hypertrophic obstructive cardiomyopathy, anemia, or more than moderate mitral or aortic heart valve disease).
  • Wheelchair bound or orthopedic inability to exercise.
  • Chronic hypoxemia with inability to exercise without oxygen supplementation.
  • Skeletal muscle myopathy.
  • History of rhabdomyolysis.
  • Participation in any clinical trial of an approved or non-approved device for the treatment of pulmonary hypertension within 30 days before screening.
  • Receipt of any investigational medicinal product within 30 days before screening.
  • Female who is pregnant, breast-feeding or intends to become pregnant or is of child-bearing potential and not using a highly effective contraceptive method.
  • Major surgery scheduled for the duration of the trial, affecting walking ability in the opinion of the investigator.
  • Any disorder, including severe psychiatric disorder, suicidal behavior within 90 days before screening, and suspected drug abuse, which in the investigator´s opinion might jeopardize subject´s safety or compliance with the protocol.

Note: Other protocol defined Inclusion/Exclusion Criteria may apply.

Eligibility last updated 3/5/2024. Questions regarding updates should be directed to the study team contact.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

Yogesh Reddy, M.B.B.S.

Open for enrollment

Contact information:

Circulatory Failure Research Team

(507) 255-2200

More information

Publications

Publications are currently not available
.
CLS-20567121

Mayo Clinic Footer